Blue Horizon International does not offer or provide medical treatment or see patients within the United States. Our cellular and exosome products are investigational and are not approved by the U.S. FDA. This website is for informational and educational purposes only and is not medical advice.

Style Sampler

Layout Style

Patterns for Boxed Mode

Backgrounds for Boxed Mode

All fields are required.

Close Appointment form

Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation

  • Home
  • Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation
Research notice: This page summarizes investigational research for scientific and educational purposes only. The cell-based products discussed are investigational, are not approved by the U.S. FDA, and have not been shown to be safe or effective for any disease or condition. Results from early-stage or retrospective studies are preliminary and are not claims about any BHI product. This is not medical advice.

Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of symptoms Related to Chronic Inflammation.

Brian M. Mehling, Louis Quartararo, Marine Manvelyan, Paul Wang, Dong-Cheng Wu

 

Full Link

The post Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation appeared first on Blue Horizon International.